PATENT CLAIM ANALYSIS

Application Number: 15752130
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "247000"]

Abstract:
The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).

Claim (Index 1):
A method of reducing cancer cell proliferation, killing, or reducing the survival of a cancer cell selected as responsive to a phosphodiesterase 3A (PDE3A) modulator, the method comprising contacting the cell with a PDE3A modulator, wherein the cell was selected as having an increase in the level of a PDE3A and/or a Schlafen 12 (SLFN12) polypeptide or polynucleotide relative to a reference, thereby reducing cancer cell proliferation, killing, or reducing the survival of the cancer cell.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.44444
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12085023', '15101865', '15250402', '13980180', '14466668']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7406798392242147
- 35 USC 102 Novelty (BERT): 0.4873153848040423
- Combined Prediction Score: 0.7153433937821975
- Mean Citation Score: 191.70974
- Max Citation Score: 193.88573
- Similarity Product: 135.99006074850976

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test